Objective-Hyperglycemia is a recognized risk factor for cardiovascular disease in diabetes. Recently, we reported that high glucose activates the Ca 2ϩ /calcineurin-dependent transcription factor nuclear factor of activated T cells (NFAT) in arteries ex vivo. Here, we sought to determine whether hyperglycemia activates NFAT in vivo and whether this leads to vascular complications. Methods and Results-An intraperitoneal glucose-tolerance test in mice increased NFATc3 nuclear accumulation in vascular smooth muscle. Streptozotocin-induced diabetes resulted in increased NFATc3 transcriptional activity in arteries of NFAT-luciferase transgenic mice. Two NFAT-responsive sequences in the osteopontin (OPN) promoter were identified. This proinflammatory cytokine has been shown to exacerbate atherosclerosis and restenosis. Activation of NFAT resulted in increased OPN mRNA and protein in native arteries. Glucose-induced OPN expression was prevented by the ectonucleotidase apyrase, suggesting a mechanism involving the release of extracellular nucleotides. The calcineurin inhibitor cyclosporin A or the novel NFAT blocker A-285222 prevented glucose-induced OPN expression. Furthermore, diabetes resulted in higher OPN expression, which was significantly decreased by in vivo treatment with A-285222 for 4 weeks or prevented in arteries from NFATc3 Ϫ/Ϫ mice. Conclusions-These results identify a glucose-sensitive transcription pathway in vivo, revealing a novel molecular mechanism that may underlie vascular complications of diabetes. (Arterioscler Thromb Vasc Biol. 2010;30:218-224.) 
T he matrix cytokine osteopontin (OPN) is emerging as a key regulator of chronic inflammatory diseases, including vascular disease. Plasma OPN levels are associated with the presence and extent of coronary artery disease, 1 restenosis after balloon angioplasty, 2 and human abdominal aortic aneurysm. 3 OPN is highly expressed in human atherosclerotic lesions and is not only a marker of inflammation but also an active player in the progression of atherosclerosis and restenosis. 4 While OPN deficiency has been shown to result in reduced atherosclerotic lesion areas, 5, 6 OPN overexpression is associated with enhanced aortic lesion size. 7 Atherosclerotic vascular disease is a major complication in diabetic patients, and the levels of OPN in vivo have been clinically associated with the progression of vascular complications. Plasma levels of OPN significantly correlate to the progression of diabetic nephropathy, 8 and OPN levels in the vitreous are enhanced in patients with diabetic retinopathy. 9 Furthermore, OPN expression is increased in the media of diabetic arteries. 10, 11 Thus, mapping the signaling pathway leading to changes in OPN expression may reveal novel pharmacological targets for prevention of vascular disease.
In the context of vascular remodeling, soluble factors, cytokines, hormones, and extracellular nucleotides have been shown to induce OPN expression. 12, 13 In particular, UTP has been demonstrated to effectively increase OPN protein production by enhanced transcription and stabilization of OPN mRNA. 14, 15 We and others have shown that stimulation of G-protein-coupled receptors effectively activates the Ca 2ϩ /calcineurin-dependent transcription factor NFAT in arterial smooth muscle. 16, 17 More recently, we have shown that high glucose activates NFAT in intact arteries ex vivo by a mechanism involving the release of extracellular nucleotides (ie, UTP, UDP) acting on P2Y receptors, leading to increased intracellular Ca 2ϩ levels and subsequent activation of the calcineurin/NFAT signaling pathway. 18 Elevated extracellular glucose levels have also been shown to induce OPN expression in rat aortic vascular smooth muscle cells (VSMCs). 19 We therefore hypothesize whether NFAT activation may be involved in the regulation of OPN expression.
The NFAT family consists of four members (NFATc1-c4) originally described in T cells but later also demonstrated in cells outside the immune system. 20 In cultured VSMCs, NFAT activation has been found to increase migration and proliferation, 17 and in a rat carotid artery injury model, blockade of NFAT signaling has been demonstrated to reduce neointima formation. 21, 22 However, this being said, downstream gene targets of NFAT are virtually undefined in VSMCs. 20 In this study, we investigate the involvement of the NFAT signaling pathway in the development of vascular complications of diabetes. We show that diabetes-induced hyperglycemia activates NFAT in vascular smooth muscle and that this leads to enhanced expression of OPN, a known marker and promoter of vascular disease.
Materials and Methods
The current study uses mice of the following strains: FVBN 9x-NFAT-luciferase reporter (NFAT-luc), BalB/c NFATc3 Ϫ/Ϫ and wild-type littermates (NFATc3 ϩ/ϩ ), and the combination of both strains (NFAT-luc/NFATc3 ϩ/ϩ , NFAT-luc/NFATc3 ϩ/Ϫ , and NFAT-luc/NFATc3 Ϫ/Ϫ ); C57Bl/6 OPN Ϫ/Ϫ and wild-type littermates; adult Naval Medical Research Institute (NMRI), C57Bl/6, and BalB/c. Aortas, cerebral arteries, and plasma were used. Hyperglycemia was induced by intraperitoneal glucose tolerance test (IP-GTT) or by streptozotocin (STZ) treatment. NFATc3 nuclear accumulation was assessed by confocal immunofluorescence, and NFAT-dependent transcriptional activity was assayed in arteries of NFAT-luc transgenic mice as previously described. 18, 23 Electrophoretic mobility shift assay was used to show binding of NFAT to the OPN promoter, and chromatin immunoprecipitation (ChIP) was used to measure NFAT enrichment on the OPN promoter, as previously described. 24, 25 OPN expression was measured by quantitative real time polymerase chain reaction, Western blotting, confocal immunofluorescence, and ELISA. Glucagon and insulin were measured by radioimmunoassay. Please see the supplemental materials for an expanded Materials and Methods section (available online at http://atvb.ahajournals.org).
Results

Hyperglycemia Induces NFATc3 Nuclear Accumulation In Vivo
Raising the blood glucose from 68.8 to 316.5 mg/dL (3.8 to 17.6 mmol/L), as measured 18 minutes after IP-GTT, significantly increases NFATc3 nuclear accumulation in cerebral arteries in vivo ( Figure 1 ). Insulin is normally secreted after a glucose challenge such as the one performed here; hence, a potential effect of insulin on NFAT activation could be anticipated. However, insulin does not promote NFATc3 nuclear accumulation in intact cerebral arteries (Supplemental Figure I , available online at http://atvb.ahajournals.org), and thus, it is more likely that the NFATc3 activation observed after IP-GTT was caused by hyperglycemia rather than by insulin.
STZ-Induced Hyperglycemia Increases NFAT-Dependent Transcriptional Activity
NFAT-luciferase reporter (NFAT-luc) mice were made diabetic by STZ treatment and luciferase activity measured in aortas. In these mice, blood glucose levels gradually increased ( Figure 2A ), and this was accompanied by an increase in NFAT-dependent transcriptional activity ( Figure  2C ). Luciferase activity correlated significantly to blood glucose values (rϭ0.661, PϽ0.05, Figure 2B ).
Similar experiments were performed in NFAT-luc mice that had been backcrossed with NFATc3 Ϫ/Ϫ mice, yielding NFAT-luc/NFATc3 ϩ/ϩ , NFAT-luc/NFATc3 ϩ/Ϫ , and NFATluc/NFATc3 Ϫ/Ϫ mice. Diabetes resulted in increased NFATdependent transcriptional activity in NFATc3-competent mice, whereas no changes were detected in heterozygous or NFATc3 null mice ( Figure 2D ). The response to hyperglycemia was more pronounced in NFAT-luc/ NFATc3 ϩ/ϩ mice than in NFAT-luc mice ( Figure 2C versus Figure 2D ), probably reflecting strain differences (FVBN versus BalB/c).
Regulation of NFAT Activity Leads to Changes in OPN Expression
Culture of intact cerebral arteries in 25 mmol/L glucose for 2 days significantly increased OPN expression in VSMCs compared with arteries cultured in 5 mmol/L glucose ( Figure 3B ). Mannitol had no effect on OPN expression, ruling out a possible osmotic effect of glucose. Glucoseinduced OPN expression was prevented by the novel NFAT blocker A-285222. 23 We have previously shown that release of extracellular nucleotides acting on P2Y receptors mediates glucose-induced NFATc3 activation and that this is prevented by incubation of arteries with the ectonucleotidase apyrase. 18 Here we show that apyrase (0.32 U/mL) prevents glucose-induced OPN expression and that culture of intact cerebral arteries with UTP results in increased OPN expression ( Figure 3A and 3C), which is prevented by A-285222. A whole set of parallel experiments was performed in mouse aortas, demonstrating that regulation of NFAT activity leads to changes in OPN expression not only in resistance arteries but also in a large conduit artery (Supplemental Figure IV ).
Absence of NFATc3 Prevents UTP-Induced Increases in OPN Expression
Cerebral arteries and aortas from NFATc3 ϩ/ϩ and NFATc3 Ϫ/Ϫ mice were cultured for 3 days in the presence or absence of UTP. In vessels from NFATc3 ϩ/ϩ mice, a significant increase in OPN expression on UTP stimulation was observed, whereas no changes were found in vessels from NFATc3 Ϫ/Ϫ animals ( Figure 4A and 4B).
NFAT Binds to Elements in the OPN Promoter Region
A search of the mouse OPN promoter region revealed four potential NFAT binding sites (Supplemental Figure II) . Two of these were located in the proximal promoter region (sites 3 and 4), whereas the other two were in the distal region, with only nine bases separating them (sites 1 and 2). Nuclear extracts from VSMCs and T cells and a labeled NFAT consensus probe were used in electrophoretic mobility shift assay experiments, resulting in the formation of two complexes (Supplemental Figure II , left gels). The slower migrating complex was competed for by the addition of a 500-fold excess of (1) unlabeled consensus oligonucleotide or (2) an oligo containing sites 1 and 2 or Figure II, right panel) , the slower migrating complex was competed for by the NFAT consensus site, by sites 1 and 2, and by site 3. Inclusion of a control antibody (anti-actin) did not disturb the binding of any of the complexes, whereas inclusion of an NFATc3 antibody largely reduced the formation of the slower migrating complex. Antibodies directed against NFATc4, NFATc1, or NFATc2 did not affect the binding of any of the complexes (Supplemental Figure III) .
To address whether NFATc3 binds to the OPN promoter in vivo, we used a quantitative ChIP assay. VSMCs from aorta explants were incubated for 3 hours in low-glucose (5 mmol/L) medium or in high-glucose (25 mmol/L) medium with or without A-285222 (1 mol/L), followed by formaldehyde fixation, immunoprecipitation of NFATc3, and quantitative real-time polymerase chain reaction analysis of immunoprecipitated DNA and input DNA using primers designed to flank the NFAT site 3 described above. As shown in Figure 4C (black bars), high glucose leads to enhanced NFATc3 binding to site 3, and this is prevented by inhibition of NFAT with A-285222. A similar pattern of response was obtained when experiments were repeated using intact aortas ( Figure 4C, gray bars) . Furthermore, we showed that culture of intact arteries in high glucose for 2 days leads to significantly increased OPN mRNA compared with arteries cultured in low glucose ( Figure 4D ). Culture per se effectively increased OPN mRNA expression, which was low but still detected in freshly dissected arteries ( Figure 4D ).
In Vivo Inhibition of NFAT Signaling Prevents Diabetes-Induced OPN Expression
Previous studies have shown that OPN expression is enhanced in arteries of diabetic patients and STZ-treated rats. In mice, increased OPN expression has been reported in arteries from db/db mice. 11 Here we provide evidence for increased OPN expression in STZ-treated mice. Eight weeks after the first STZ injection, subvalvular aortic sections were imaged using confocal immunofluorescence. Expression was significantly increased in the media of diabetic animals and correlated with blood glucose levels (rϭ0.639, PϽ0.001, Supplemental Figure V) . OPN expression in valve leaflets was lower than in the media, but it still exhibited a positive correlation to blood glucose (rϭ0.655, PϽ0.001, not shown). Plasma levels of OPN were significantly increased in diabetic animals and correlated to blood glucose (rϭ0.588, PϽ0.005, Supplemental Figure V) .
We then tested whether inhibition of NFAT signaling in vivo had any impact on OPN expression in aorta. For this, diabetic and control mice were treated with A-285222 or vehicle, administered IP once a day for the duration of the experiment. STZ-treated mice developed diabetes during week 2, whereas blood glucose remained unchanged in control mice ( Figure 5A ). After 4 weeks, OPN expression was significantly increased in aortas from diabetic animals compared with those from normoglycemic mice ( Figure  5B ). Inhibition of NFAT signaling with A-285222 significantly reduced OPN expression in aorta. To test the specific involvement of NFATc3 isoform in the regulation of OPN expression in vivo, similar experiments were performed in NFATc3 ϩ/ϩ and NFATc3 Ϫ/Ϫ mice. As shown in Figure 5D , OPN expression was significantly increased in the aorta of STZ-treated NFATc3 ϩ/ϩ mice, whereas the effect was blunted in STZ-treated NFATc3 Ϫ/Ϫ mice, despite the fact that they developed hyperglycemia to the same extent as NFATc3 ϩ/ϩ mice ( Figure 5C ).
During week 2, diabetic mice treated with A-285222 (0.29 mg/kg body weight) exhibited more pronounced hyperglycemia and weight loss than diabetic mice receiving saline (9.6% versus 2.2% weight loss at day 16). In an attempt to prevent further weight loss, we adjusted the dose of A-285222 to 0.15 mg/kg body weight from day 16 until the end of the experiment. This lower concentration was better tolerated, since the rate of weight loss decreased. Strong evidence has been provided for the involvement of NFAT the regulation of insulin transcription in ␤-cells 26 ; therefore, we asked whether the differences in blood glucose levels could be due to NFAT-inhibition on pancreatic islets. Reduced insulin production was observed in 6 of 8 of the STZ ϩ A-285222 treated mice, as shown by their lower insulinogenic index compared with STZtreated mice; plasma glucagon levels were not affected by A-285222 treatment (Supplemental Figure VI) . Treatment with A-285222 did not affect glycemia or body weight in nondiabetic animals (3.2% versus 5.5% weight loss for A-285222 versus control).
Discussion
In this study, we demonstrate for the first time that changes in blood glucose levels are readily detected by NFATc3 in arterial smooth muscle in vivo and that the calcineurin/ NFATc3 signaling pathway regulates the expression of OPN, which is a key player in the development of vascular disease. Our major findings are as follows: (1) changes in extracellular glucose activate NFATc3 signaling in vivo;
(2) NFATc3 has the ability to bind to at least one NFAT binding site (site 3) in the mouse promoter region of OPN;
(3) NFATc3 activation leads to increased OPN mRNA and protein expression in intact arteries; (4) glucose-induced OPN expression is dependent on the release of extracellular nucleotides acting on P2Y membrane receptors; (5) glucose-induced OPN expression is prevented by pharmacological inhibition of calcineurin/NFAT signaling; and (6) STZ-induced diabetes increases OPN expression in the ascending and thoracic aorta, vascular segments particularly prone to atherosclerosis in diabetic patients, and this is prevented by in vivo treatment with the NFAT inhibitor A-285222 or by lack of NFATc3 protein in arteries from NFATc3 Ϫ/Ϫ mice. These results suggest a role for NFATc3 as a metabolic sensor in the vascular wall that is of potential relevance for vascular dysfunction in diabetes.
Our previous ex vivo studies show that raising extracellular glucose elicits a time-and dose-dependent increase in NFATc3 nuclear accumulation, with a maximum response obtained at 360 mg/dL glucose (20 mmol/L) and after 20 minutes of exposure. 18 The data presented here demonstrate a similar activation pattern in vivo, with significant NFATc3 nuclear accumulation at an average blood glucose level of 316.5 mg/dL (17.6 mmol/L) 18 minutes post-IP-GTT. Based on published data describing NFATc3 nuclear export rates, 27 a transient NFATc3 response can be predicted after an IP-GTT, with restored NFATc3 distribution once blood glucose is normalized. The transient nature of the response may thus allow the system to sense new changes in glycemia and generate a new wave of transcriptional activity. This could be important in the clinical situation because transient hyperglycemic peaks may be sufficient for NFAT activation. Another interesting observation is that basal levels of NFATc3 nuclear accumulation measured in arteries from control mice ( Figure 1A and 1B), which are perfusion fixed under pressurized conditions, are higher than the levels measured in previous ex vivo experiments in arteries fixed under nonpressurized conditions. This seems to agree with evidence showing that intraluminal pressure is a stimulus for NFATc3 nuclear accumulation. 28 The regulation of OPN transcription has been suggested to require the concerted action of various transcription factors in VSMCs. The NFAT-binding site 3 identified here is located within the proximal region where both activator protein (AP)-1 and upstream transcription factor (USF) have been shown to bind. Although we did not test for possible synergisms between NFAT and AP-1 or USF, it is possible that all three proteins interact to overcome stereological constraints and enable stable assembly within this limited DNA region. Interestingly, in experiments using luciferase-reporter plasmids containing different lengths of the 5Ј region of the rat OPN promoter, basal activity of the OPN promoter is greatly reduced when the regions harboring the NFAT site 3 investigated here are deleted. 14, 29 On the other hand, the promoter regions identified to mediate transcription induced by glucose-(Ϫ112/Ϫ62 and Ϫ83/Ϫ45) and UTP-(Ϫ76/ϩ1) are adjacent to NFAT site 3 but do not overlap it. 29, 30 A possible explanation for this inconsistency is the incomplete sequence homology between species (mouse versus rat). Nevertheless, the fact that pharmacological or genetic inhibition of NFAT signaling prevents glucose-and UTPmediated OPN protein production in intact arteries, together with the ChIP results, suggests that NFAT may bind to the OPN promoter under these conditions.
To date, it is not clear what the exact role of individual NFAT isoforms is in the vasculature. Although all NFAT isoforms are expressed in aortic VSMCs (data not shown), the luciferase experiments using NFAT-luc/NFATc3 ϩ/ϩ , NFAT-luc/NFATc3 ϩ/Ϫ , and NFAT-luc/NFATc3 Ϫ/Ϫ mice demonstrate that NFATc3 is responsible for the increased NFAT-dependent transcriptional activity measured in diabetic animals. Electrophoretic mobility shift assay results suggest that probably only NFATc3 is able to bind to the identified NFAT sites in the OPN promoter. ChIP results confirm that this isoform binds to the OPN promoter in vivo. The experiments using NFATc3 Ϫ/Ϫ mice further support a role for this isoform in the regulation of OPN expression. Recent studies have shown that activation of NFAT, and more specifically NFATc3, promotes VSMC proliferation and interleukin 6 production in human resistance arteries, 23 drives the expression of the inflammatory protein vascular cell adhesion molecule 1, 31 and plays a role in pulmonary hypertension. 32 Also, NFATc3 downregulates the expression of voltage-gated K ϩ channels (Kv2.1) and the ␤1 subunit of large-conductance, Ca 2ϩactivated K ϩ channels, mediating angiotensin II-induced hypertension. 33 Taken together, these events all contribute to arterial dysfunction, and if combined with enhanced OPN expression, they may intensify the severity of vascular disease.
Several important findings emerged from the in vivo treatment of mice with the NFAT blocker A-285222. Interestingly, the arteries of mice treated with A-285222 exhibit dramatically reduced OPN expression despite glucose levels even higher than those in nontreated diabetic mice. Also, treatment of normoglycemic mice with A-285222 resulted in OPN expression below basal levels, supporting the idea of a constitutively active NFAT signaling pathway under control conditions. This is the first in vivo study in mice using A-285222. The only pharmacokinetic or pharmacodynamic data available are from a study by Birsan et al 34 in which cynomolgus monkeys were treated with A-285222 orally twice a day for several days. As early as after 1 day, a marked inhibition of NFAT signaling, as assessed by reduced T-cell cytokine production, was observed. Birsan et al 34 also showed that treatment with A-285222 was possible over long periods of time and that no neurotoxicity developed if A-285222 is administered at 5 to 7.5 mg/kg body weight. In our hands, a much lower dose was required for the clear vascular effects reported here (0.15 to 0.29 mg/kg body weight). However, the undesired effects observed on ␤-cell function point out the need for additional adjustments of the drug dose and/or a more local delivery of the compound.
The concept of the calcineurin/NFAT signaling pathway as a sensor in the vascular wall that is of potential relevance for vascular dysfunction in diabetes is novel. Despite all the evidence linking hyperglycemia to increased risk of microvascular and macrovascular disease, 35, 36 the molecular mechanisms underlying vascular damage are not completely understood. Most studies focus on the generation of oxidative stress as the pathogenic mechanism linking hyperglycemia to endothelial dysfunction, an initial step in atherosclerosis. 37 In endothelial cells, hyperglycemia promotes the production of reactive oxygen species, which in turn affects four seemingly independent biochemical pathways: it activates the aldose reductase, protein kinase C, and hexosamine pathways and increases advanced glycation end products. 38 Activation of these pathways triggers the production of atherogenic circulating adhesion molecules and inflammatory cytokines. The identification of an additional pathway in this study, able to sense hyperglycemia in both large and resistance arteries, adds a new layer of complexity to the process of diabetic angiopathy and reveals a potential therapeutic target and biomarker.
